Literature DB >> 10391854

Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic.

X Yu1, Y Sun, C Frasch, N Concepcion, M H Nahm.   

Abstract

We measured the capacity to opsonize Streptococcus pneumoniae serotype 6B and estimated the concentration of immunoglobulin G anti-6B capsular polysaccharide (PS) antibodies in 25 pre- and postimmune sera from adults immunized with a pneumococcal PS vaccine. We first studied two postvaccination serum samples displaying less opsonophagocytic capacity than expected. The majority of anti-6B antibodies in the two samples reacted with the capsular PSs of several unrelated serotypes (2, 4, 9V, 19F, and 23F) and with the lysate of noncapsulated S. pneumoniae bacteria but not with C-PS. The non-type-specific antibodies accounted for at least one-half of anti-6B antibodies in 40% of prevaccination sera and 10% of postvaccination sera from adults. The non-type-specific antibodies could be demonstrated in the enzyme-linked immunosorbent assays (ELISAs) for pneumococcal antibodies to other serotypes (4, 9V, 18C, 19F, and 23F). The nonspecific antibodies appear to bind a contaminant(s) in the current preparations of capsular PS. ELISA for antibodies to pneumococcal capsules may not be serotype specific for some samples.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10391854      PMCID: PMC95719          DOI: 10.1128/CDLI.6.4.519-524.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  16 in total

1.  Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae.

Authors:  D E Briles; M J Crain; B M Gray; C Forman; J Yother
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

2.  Opsonophagocidal activity in sera from infants and children immunized with Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate).

Authors:  B M Gray
Journal:  Pediatrics       Date:  1990-04       Impact factor: 7.124

3.  Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide.

Authors:  D M Musher; M J Luchi; D A Watson; R Hamilton; R E Baughn
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

4.  Capsulation of pneumococcus with soluble cell wall-like polysaccharide. II. Nonidentity of cell wall and soluble cell wall-like polysaccharides derived from the same and from different pneumococcal strains.

Authors:  G Schiffman; D L Bornstein; R Austrian
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

5.  Artifacts with the thiocyanate elution method for estimating relative antibody avidity.

Authors:  B M Gray; D R Shaw
Journal:  J Immunol Methods       Date:  1993-01-04       Impact factor: 2.303

Review 6.  Pneumococcal disease: prospects for a new generation of vaccines.

Authors:  G R Siber
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

Review 7.  Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups.

Authors:  J B Robbins; R Austrian; C J Lee; S C Rastogi; G Schiffman; J Henrichsen; P H Mäkelä; C V Broome; R R Facklam; R H Tiesjema
Journal:  J Infect Dis       Date:  1983-12       Impact factor: 5.226

8.  Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4.

Authors:  D M Musher; B Johnson; D A Watson
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

9.  Emergence of drug-resistant pneumococcal infections in the United States.

Authors:  R F Breiman; J C Butler; F C Tenover; J A Elliott; R R Facklam
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

10.  Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae.

Authors:  G Vitharsson; I Jónsdóttir; S Jónsson; H Valdimarsson
Journal:  J Infect Dis       Date:  1994-09       Impact factor: 5.226

View more
  30 in total

1.  Chromogenic assay measuring opsonophagocytic killing capacities of antipneumococcal antisera.

Authors:  J S Lin; M K Park; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  Towards a synthetic pneumococcal vaccine: synthetic oligosaccharides as tools for improving the specificity of enzyme-linked immunosorbent assays.

Authors:  H Snippe; W T Jansen; J P Kamerling; D J Lefeber
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

Review 3.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

4.  Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children.

Authors:  Anu Soininen; Maijastiina Karpala; Sirkka-Liisa Wahlman; Hannele Lehtonen; Helena Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

Review 5.  Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies.

Authors:  R A Fleck; S Romero-Steiner; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

6.  Subclass distribution of natural salivary IgA antibodies against pneumococcal capsular polysaccharide of type 14 and pneumococcal surface adhesin A (PsaA) in children.

Authors:  B Simell; T Kilpi; H Käyhty
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

7.  Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice.

Authors:  W T Jansen; S Hogenboom; M J Thijssen; J P Kamerling; J F Vliegenthart; J Verhoef; H Snippe; A F Verheul
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

8.  Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines.

Authors:  Jan T Poolman; Carl E Frasch; Helena Käyhty; Pascal Lestrate; Shabir A Madhi; Isabelle Henckaerts
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

9.  Enzyme-linked immunosorbent assay for measuring antibodies to pneumococcal polysaccharides for the PNEUMOVAX 23 vaccine: assay operating characteristics and correlation to the WHO international assay.

Authors:  Rocio D Marchese; Neil T Jain; Joseph Antonello; Laura Mallette; Kristin L Butterfield-Gerson; Jennifer Raab; Pamela Burke; Cheryl Schulman; Hilary Adgate; Daniel J Sikkema; Narendra Chirmule
Journal:  Clin Vaccine Immunol       Date:  2006-08

10.  The effect of age on the response to the pneumococcal polysaccharide vaccine.

Authors:  Hyunju Lee; Moon H Nahm; Kyung-Hyo Kim
Journal:  BMC Infect Dis       Date:  2010-03-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.